Login
Subscribe
First Person Dosed in Novel Gene Editing Clinical Trial
First Person Dosed in Novel Gene Editing Clinical Trial
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
DNA base modifications
Contributors
Catherine Offord and Jef Akst | Sep 1, 2017 | 3 min read
Meet some of the people featured in the September 2017 issue of The Scientist.